02480 綠竹生物 - B
LUZHU BIOTECH-B
LUZHU BIOTECH-B
| Listing Date | 2023/05/08 |
| Listing Price | 32.800 |
Quote
Subscription Result
- Subscription Rate3.25x
- Guarantee One Lot Size6 lot
- One Lot Success Rate50%
|
|
|
|
|
|
|
|
|
|
IPO Detail
COMPANY PROFILE
Beijing Luzhu Biotechnology Co. are a biotechnology company committed to developing innovative human vaccines and therapeutic biologics to prevent and control infectious diseases and treat cancer and autoimmune diseases.
--
Its product pipeline consisted of three clinical-stage product candidates, including Core Product LZ901, and four pre-clinical-stage product candidates. LZ901, its Core Product and independently developed recombinant herpes zoster vaccine candidate. It is for adults aged 50 years and older. LZ901 prevents the occurrence of herpes zoster and related complications caused by herpes zoster.
--
The Group had three invention patents granted and eight registered trademarks in the PRC, one invention patent granted in Russia and one registered trademark in Hong Kong. It had filed eight patent applications worldwide. Among its patent portfolio, two invention patents and seven pending patent applications are relating to Core Product.
BASIC INFORMATION
| Market | Hong Kong (Main Board) |
| Business Nature | Health Care |
| Major Business Area | China |
| Board Lot | 200 |
GLOBAL OFFERING
| No. of Offer Shares | 10.39M H shares |
| No. of International Offer Shares | 9.35M H shares |
| No. of HK Offer Shares | 1.04M H shares |
| Offer Price | $32.80 - $41.65 |
| Stock Code | 2480 |
| Sponsor(s) | China International Capital Corporation Hong Kong Securities Limited |
| Underwriter(s) | China International Capital Corporation Hong Kong Securities Limited, Guotai Junan Securities (Hong Kong) Limited, CCB International Capital Limited, Guosen Securities (HK) Capital Company Limited, Fosun International Securities Limited, Patrons Securities Limited, BOCI Asia Limited, Eddid Securities and Futures Limited, ABCI Securities Company Limited, Valuable Capital Limited, Futu Securities International (Hong Kong) Limited, CNCB (Hong Kong) Capital Limited, Central China International Capital Limited, Dragonstone Capital Management Limited, GF Securities (Hong Kong) Brokerage Limited, CEB International Capital Corporation Limited |
TIME TABLE
| Application Period | Apr 25 (Tue) - noon, Apr 28 (Fri) |
| Price Determination Date | Apr 28 (Fri) |
| Result Announcement Date | On or before May 05 (Fri) |
| Result Announcement Date | On or before May 05 (Fri) |
| Result Announcement Date | On or before May 05 (Fri) |
| Dealings in Shares commence on | May 08, 2023. (Mon) |
Reallocation of Shares Offered
| Times of HK Offer Shares Subscription | 15X - 50X | 50X - 100X | Over 100X |
| % of total shares reallocated to HK Offer | 30% | 40% | 50% |
Sales Statistics (HKD)
| Offer Price | $32.80 - $41.65 |
| Capitalization (H Shares) | 6.64B - 8.43B |
| NAV / share ($) | $6.58 - $7.03 (Unaudited pro forma adj NAV / share) |
Use Of Proceeds
| Assuming the offer price being at HKD 37.23, the net proceeds raised would be HKD 284.00M, of which |
| 58.2% : Clinical development, manufacturing and commercialization of Core Product LZ901 |
| 22.1% : Clinical development and manufacturing of K3 |
| 16.1% : Construction of second-phase commercial manufacturing facility in Zhuhai |
| 3.6% : Working capital |
Related Document
| Prospectus |  Chinese Version | English Version |
| Remark： | The above information is referenced from the prospectus. |
| All data is calculated from the non- exercise rights(if applicable). |
Name︰
--
--
--
Subscription --
Result Announcement --
Listing --Offer Price︰--
| Currency | : |
| Listing Price | : |
| Board Lot | : |
| Admission Fee* |
: |
| Subscribing Lot | : |
| Subscribing Fee | : |
| Subscribing Amount | : |
*Admission fees include brokerage of 1%, SFC transaction levy of 0.0027%, Stock Exchange trading fee of 0.005% and FRC transaction levy of 0.00015% (i.e. 1.0077% in total).